

# **Cancer Biomarker Testing Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023**

<https://marketpublishers.com/r/C4F68D86856EN.html>

Date: December 2017

Pages: 195

Price: US\$ 4,400.00 (Single User License)

ID: C4F68D86856EN

## **Abstracts**

Cancer Biomarker Testing Market: Biomarker is any of body molecules that can be measured to assess the health. Molecules can be obtained from, body fluids, tissue or blood. Biomarker testing is also known as genetic testing or molecular testing. Biomarker test is a group of tests that look for these molecular signs of health so that doctors can plan best care. Cancer is referred as abnormal growth of the cells. Cancer biomarker is a process or substance that indicates the presence of cancer in the body. Genetic, epigenetic, glyceimic, proteomic, and imaging biomarkers are used for cancer diagnosis, prognosis, and epidemiology. These cancer biomarkers used as risk indicators for various types of cancer such as lung cancer, breast cancer and prostate cancer among the others. Key cancer biomarkers include SCC, CEA, NSE Cyfra 21, PSA (prostate cancer), TPA (Lung cancer), CA15-3, EGF R, Cytokeratin 4 (breast cancer) and BRCA ½.

### **Cancer Biomarker Testing Market**

The cancer biomarker test market is driven by rising prevalence of cancer worldwide. World Health Organization (WHO) stated that cancer is one of the leading causes of mortality and morbidity worldwide, with approximately 14 Mn new cases in 2012. The number of new cases is expected to rise about 70% over the coming 2 decades. In addition, increase in awareness in public and healthcare professionals regarding early diagnostic procedures, rise in government and NGO's funding for oncology are expected to bolster the cancer biomarker testing market. Furthermore, the development of companion diagnostics and recent breakthrough in detection techniques such as

proteomics, metabolomics, genomics and transcriptomics are further expected to boost the cancer biomarker test market. However, high cost for biomarker tests, low detection rates and regulatory policies are expected to hamper the cancer biomarker test market.

Cancer biomarker testing market segmented based on type of cancer, application, bio molecule and end user

Based on type of cancer, cancer biomarker test market is segmented into

- Cervical cancer
- Lung Cancer
- Collateral Cancer
- Liver Cancer
- Prostate Cancer
- Breast Cancer
- Others

Based on application, cancer biomarker test market is segmented into

- Drug Discovery and Development
- Personalised Medicine
- Diagnosis
- Others

Based on end-user, cancer biomarker test market is segmented into

- Hospitals
- Cancer diagnostic Centres
- Research Institutes
- Others

The global cancer biomarker test market is expected to grow with significant CAGR during forecast period. Market players are carrying out collaborations, partnerships, and acquisitions as key development strategies to enhance the market share. For instance, in March 2017, Foundation Medicine and Bristol-Myers Squibb entered collaboration to understand tumour profile and its microenvironment to predict patient's response to cancer immunotherapy. Using Foundation Medicine's foundation genomic profiling assay, the firm will look at tumour mutational burden and microsatellite instability in

patients enrolled in clinical trials for Bristol-Myers Squibb (BMS) cancer drugs. For instance, in October 2016, Arquer Diagnostics Ltd. (Arquer), and University of Sunderland are collaborated to investigate noninvasive specimen preparation techniques that will facilitate the use of Arquer's MCM5-ELISA test in a wide range of cancers. In April 2016, Stemcentrix acquired by AbbiVe along with its lead late stage biomarker rovalpituzumab tesirine (Rova-T), that helps to identify tumour cells.

Geographically cancer biomarker testing market segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is expected to be a major market for cancer biomarker test market owing to increase in research and development activities to diagnose and treating cancer and rise in prevalence of cancer. According to American Cancer Society (ACS), in 2017, it estimates 1,688,780 new cancer cases are diagnosed and 600,920 cancer deaths in the U.S. alone. Asia-Pacific region is expected to be fastest growing market due to increase in demand for the non-invasive techniques in diagnosis and prevention of cancer, high prevalence of cancer conditions in the region.

Some of the players in cancer biomarker test market are Thermo Fisher Scientific (Affymetrix Inc.) (U.S.), Abbott Laboratories (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc. (U.S.), Arquer Diagnostics Ltd. (U.K.), Illumina, Inc. (U.S.), Qiagen (Germany), Agilent Technologies (U.S.), Merck & Co. Inc. (U.S.), Becton Dickinson and Company (U.S.), and Hologic Inc. (U.S.) to name a few.

In 2015, Abbot Laboratories acquired exclusive rights for FGFR3 gene mutations to detect bladder cancer. FGFR3 developed at Institute Curie, it is a gene mutation and useful for early detection, disease monitoring, and prognosis of bladder cancer through tissue and urine-based testing

## Contents

### **1. EXECUTIVE SUMMARY**

### **2. GLOBAL CANCER BIOMARKER TESTING MARKET INTRODUCTION**

2.1. Global Cancer Biomarker Testing Market – Taxonomy

2.2. Global Cancer Biomarker Testing Market –Definitions

2.2.1. Type of Cancer

2.2.2. Application

2.2.3. End User

### **3. GLOBAL CANCER BIOMARKER TESTING MARKET DYNAMICS**

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Cancer Biomarker Testing Market Dynamic Factors - Impact Analysis

3.6. Global Cancer Biomarker Testing Market – Regulations

3.6.1. U.S.

3.6.2. Europe

3.7. Global Cancer Biomarker Testing Market –Trends

### **4. GLOBAL CANCER BIOMARKER TESTING MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023**

4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

### **5. GLOBAL CANCER BIOMARKER TESTING MARKET , BY TYPE OF CANCER, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)**

5.1. Cervical Cancer

5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Lung Cancer

- 5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 5.2.3. Market Opportunity Analysis
- 5.3. Collateral Cancer
  - 5.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 5.3.3. Market Opportunity Analysis
- 5.4. Liver Cancer
  - 5.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 5.4.3. Market Opportunity Analysis
- 5.5. Prostate Cancer
  - 5.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 5.5.3. Market Opportunity Analysis
- 5.6. Breast Cancer
  - 5.6.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 5.6.3. Market Opportunity Analysis
- 5.7. Others
  - 5.7.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 5.7.3. Market Opportunity Analysis

## **6. GLOBAL CANCER BIOMARKER TESTING MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 – 2023**

- 6.1. Drug Discovery and Development
  - 6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 6.1.3. Market Opportunity Analysis
- 6.2. Personalised Medicine
  - 6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 6.2.3. Market Opportunity Analysis
- 6.3. Diagnosis
  - 6.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 6.3.3. Market Opportunity Analysis

#### 6.4. Others

- 6.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 6.4.3. Market Opportunity Analysis

### **7. GLOBAL CANCER BIOMARKER TESTING MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 – 2023**

#### 7.1. Hospitals

- 7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 7.1.3. Market Opportunity Analysis

#### 7.2. Cancer Diagnostic Centres

- 7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 7.2.3. Market Opportunity Analysis

#### 7.3. Research Institutes

- 7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 7.3.3. Market Opportunity Analysis

#### 7.4. Others

- 7.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 7.4.3. Market Opportunity Analysis

### **8. GLOBAL CANCER BIOMARKER TESTING MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)**

#### 8.1. North America

- 8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.1.3. Market Opportunity Analysis

#### 8.2. Europe

- 8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.2.3. Market Opportunity Analysis

#### 8.3. Asia-Pacific

- 8.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

### 8.3.3. Market Opportunity Analysis

## 8.4. Latin America

### 8.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

### 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

### 8.4.3. Market Opportunity Analysis

## 8.5. Middle East and Africa

### 8.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

### 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

### 8.5.3. Market Opportunity Analysis

## 8.6. Global Cancer Biomarker Testing Market - Opportunity Analysis Index, By Type of Cancer, By Application, By End Use and Region, 2017 – 2023

## **9. NORTH AMERICA CANCER BIOMARKER TESTING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)**

### 9.1. Type of Cancer Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

#### 9.1.1. Cervical cancer

#### 9.1.2. Lung Cancer

#### 9.1.3. Collateral Cancer

#### 9.1.4. Liver Cancer

#### 9.1.5. Prostate Cancer

#### 9.1.6. Breast Cancer

#### 9.1.7. Others

### 9.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

#### 9.2.1. Drug Discovery and Development

#### 9.2.2. Personalised Medicine

#### 9.2.3. Diagnosis

#### 9.2.4. Others

### 9.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

#### 9.3.1. Hospitals

#### 9.3.2. Cancer Diagnostic Centres

#### 9.3.3. Research Institutes

#### 9.3.4. Others

### 9.4. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

#### 9.4.1. U.S.



#### 9.4.2. Canada

9.5. North America Cancer Biomarker Testing Market - Opportunity Analysis Index, By Type of Cancer, By Application, By End Use and Country, 2017 – 2023

9.6. North America Cancer Biomarker Testing Market Dynamics – Trends

### **10. EUROPE CANCER BIOMARKER TESTING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)**

10.1. Type of Cancer Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1. Cervical cancer

10.1.2. Lung Cancer

10.1.3. Collateral Cancer

10.1.4. Liver Cancer

10.1.5. Prostate Cancer

10.1.6. Breast Cancer

10.1.7. Others

10.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.2.1. Drug Discovery and Development

10.2.2. Personalised Medicine

10.2.3. Diagnosis

10.2.4. Others

10.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.3.1. Hospitals

10.3.2. Cancer Diagnostic Centres

10.3.3. Research Institutes

10.3.4. Others

10.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

10.4.1. Germany

10.4.2. UK

10.4.3. France

10.4.4. Spain

10.4.5. Italy

10.4.6. Russia

10.4.7. Poland

10.4.8. Rest of Europe



10.5. Europe Cancer Biomarker Testing Market - Opportunity Analysis Index, By Type of Cancer, By Application, By End Use and Country, 2017 – 2023

10.6. Europe Cancer Biomarker Testing Market Dynamics – Trends

## **11. ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)**

11.1. Type of Cancer Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1. Cervical cancer

11.1.2. Lung Cancer

11.1.3. Collateral Cancer

11.1.4. Liver Cancer

11.1.5. Prostate Cancer

11.1.6. Breast Cancer

11.1.7. Others

11.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.2.1. Drug Discovery and Development

11.2.2. Personalised Medicine

11.2.3. Diagnosis

11.2.4. Others

11.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.3.1. Hospitals

11.3.2. Cancer Diagnostic Centres

11.3.3. Research Institutes

11.3.4. Others

11.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

11.4.1. Japan

11.4.2. China

11.4.3. India

11.4.4. ASEAN

11.4.5. Australia & New Zealand

11.4.6. Rest of Asia-Pacific

11.5. Asia-Pacific Cancer Biomarker Testing Market - Opportunity Analysis Index, By Type of Cancer, By Application, By End Use and Country, 2017 – 2023

11.6. Asia-Pacific Cancer Biomarker Testing Market Dynamics – Trends

## **12. LATIN AMERICA CANCER BIOMARKER TESTING MARKET ANALYSIS, 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)**

12.1. Type of Cancer Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

- 12.1.1. Cervical cancer
- 12.1.2. Lung Cancer
- 12.1.3. Collateral Cancer
- 12.1.4. Liver Cancer
- 12.1.5. Prostate Cancer
- 12.1.6. Breast Cancer
- 12.1.7. Others

12.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

- 12.2.1. Drug Discovery and Development
- 12.2.2. Personalised Medicine
- 12.2.3. Diagnosis
- 12.2.4. Others

12.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

- 12.3.1. Hospitals
- 12.3.2. Cancer Diagnostic Centres
- 12.3.3. Research Institutes
- 12.3.4. Others

12.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

- 12.4.1. Brazil
- 12.4.2. Mexico
- 12.4.3. Argentina
- 12.4.4. Venezuela
- 12.4.5. Rest of Latin America

12.5. Latin America Cancer Biomarker Testing Market - Opportunity Analysis Index, By Type of Cancer, By Application, By End Use and Country, 2017 – 2023

12.6. Latin America Cancer Biomarker Testing Market Dynamics – Trends

## **13. MIDDLE EAST AND AFRICA CANCER BIOMARKER TESTING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)**

13.1. Type of Cancer Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

- 13.1.1. Cervical cancer
- 13.1.2. Lung Cancer
- 13.1.3. Collateral Cancer
- 13.1.4. Liver Cancer
- 13.1.5. Prostate Cancer
- 13.1.6. Breast Cancer
- 13.1.7. Others

13.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

- 13.2.1. Drug Discovery and Development
- 13.2.2. Personalised Medicine
- 13.2.3. Diagnosis
- 13.2.4. Others

13.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

- 13.3.1. Hospitals
- 13.3.2. Cancer Diagnostic Centres
- 13.3.3. Research Institutes
- 13.3.4. Others

13.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

- 13.4.1. Gulf Cooperation Council (GCC) Countries
- 13.4.2. Israel
- 13.4.3. South Africa
- 13.4.4. Rest of MEA

13.5. MEA Cancer Biomarker Testing Market - Opportunity Analysis Index, By Type of Cancer, By Application, By End Use and Country, 2017 – 2023

13.6. MEA Cancer Biomarker Testing Market Dynamics – Trends

## **14. COMPETITION LANDSCAPE**

14.1. Strategic Dashboard of Top Market Players

14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

- 14.2.1. Thermo Fisher Scientific (Affymetrix Inc.) (U.S.)
- 14.2.2. Abbott Laboratories (U.S.)
- 14.2.3. F. Hoffmann-La Roche Ltd. (Switzerland)

- 14.2.4. AbbVie Inc. (U.S.)
- 14.2.5. Arquer Diagnostics Ltd. (U.K.)
- 14.2.6. Illumina, Inc. (U.S.)
- 14.2.7. Qiagen (Germany)
- 14.2.8. Agilent Technologies (U.S.)
- 14.2.9. Merck & Co. Inc. (U.S.)
- 14.2.10. Becton Dickinson and Company (U.S.)
- 14.2.11. Hologic Inc. (U.S.)

## **15. RESEARCH METHODOLOGY**

## **16. KEY ASSUMPTIONS AND ACRONYMS**

## I would like to order

Product name: Cancer Biomarker Testing Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Product link: <https://marketpublishers.com/r/C4F68D86856EN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C4F68D86856EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

